Author

Hong Qin

Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

Observed institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)

OpenAlex ID: A5130717152

CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study

2026 · Piyush Gondaliya, Yan Luo, et al. · Molecular Therapy Oncology · 1

Abstract 4283: CD3-positive allogeneic CAR T-cells: A novel platform with persistence, BiTE-capture, and no alloreactivity

2026 · Tanya Hundal, Yan Luo, et al. · Cancer Research

Abstract 3719: From gene to bedside: Mayo Clinic’s first-in-house BAFF-R CAR-T

2026 · Yan Luo, Shaohua Guo, et al. · Cancer Research

Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma

2026 · Mohamed A. Kharfan-Dabaja, Tea Reljic, et al. · Current Research in Translational Medicine

464 Dual-Strike Immunotherapy: Intracranial PD-L1–Directed MC9999 CAR T Cells Eradicate Glioblastoma and Reprogram the Tumor Microenvironment

2026 · Loizos Michaelides, Jesus Emiliano Sanchez-Garavito, et al. · Neurosurgery

Impact of mental health on outcomes of patients with relapsed and/or refractory diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy

2026 · Mohamed A. Kharfan-Dabaja, Athanasios Tsalatsanis, et al. · Hematology/Oncology and Stem Cell Therapy

Works count: 6

Citation count: 1

H-index: 1

I10-index: